Literature DB >> 21896703

Varenicline: quantifying the risk.

Edward N Squire.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21896703      PMCID： PMC3168636          DOI： 10.1503/cmaj.111-2070

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  2 in total

1.  Varenicline: quantifying the risk.

Authors:  David J Woods; Mark D Caswell
Journal:  CMAJ       Date:  2011-09-06       Impact factor: 8.262

Review 2.  Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; John G Spangler; Curt D Furberg
Journal:  CMAJ       Date:  2011-07-04       Impact factor: 8.262
  2 in total
  3 in total

1.  Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness.

Authors:  Shadi Nahvi; Bryan Wu; Kimber P Richter; Steven L Bernstein; Julia H Arnsten
Journal:  Drug Alcohol Depend       Date:  2013-01-17       Impact factor: 4.492

2.  Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study.

Authors:  Henrik Svanström; Björn Pasternak; Anders Hviid
Journal:  BMJ       Date:  2012-11-08

Review 3.  Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.

Authors:  Judith J Prochaska; Joan F Hilton
Journal:  BMJ       Date:  2012-05-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.